A Phase II Study of the Beta-blocker Propranolol Alone and With Chemotherapy in Patients Receiving Neoadjuvant Treatment for Newly Diagnosed Breast Cancer

Trial Profile

A Phase II Study of the Beta-blocker Propranolol Alone and With Chemotherapy in Patients Receiving Neoadjuvant Treatment for Newly Diagnosed Breast Cancer

Recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Feb 2016

At a glance

  • Drugs Propranolol (Primary) ; Cyclophosphamide; Doxorubicin; Taxanes; Trastuzumab
  • Indications Advanced breast cancer
  • Focus Adverse reactions; Biomarker; Pharmacodynamics
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 03 Feb 2016 Planned primary completion date changed from 1 Oct 2015 to 1 Oct 2016, as reported by ClinicalTrials.gov record.
    • 11 Jul 2014 Planned End Date changed from 1 Oct 2014 to 1 Oct 2016 according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top